Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Infections

Rare Diseases

Recurrence

Melanoma

Lentigo

Adenoviridae Infections

Hutchinson's Melanotic Freckle

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Lentigo Maligna Melanoma

Acral Lentiginous Melanoma

Superficial Spreading Melanoma

Nodular Melanoma

Neuroendocrine Tumor

Neuroepithelioma

Anti-Infective Agents

All Drugs and Chemicals

Ganciclovir

Ganciclovir triphosphate

Antiviral Agents

Enzyme Inhibitors

adenovirus RSV-TK

ganciclovir

John C. Morris, MD

RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.

PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.

OBJECTIVES: I. Determine the maximum tolerated dose of ganciclovir administered IV every 12 hours for 7 days in combination with adenovirus RSV-TK administered by direct intralesional injection in patients with cutaneous or subcutaneous metastatic malignant melanoma. II. Determine the dose limiting toxicities of this regimen in this patient population. III. Evaluate the response (both local and at distant metastatic sites), duration of response, response by ganciclovir dose, and any impact local treatment with adenovirus RSV-TK and ganciclovir "suicide" gene therapy may have on overall survival in these patients.

OUTLINE: This is a dose escalation study of ganciclovir. Patients are stratified according to response of the index lesion and other metastatic disease sites. Patients receive an intratumoral injection of adenovirus RSV-TK on day 1. Ganciclovir IV is administered every 12 hours on days 3-10 for a total of 14 doses. Patients sustaining a partial response (PR) or complete response (CR) may be retreated 2 weeks after documented PR or CR. Cohorts of 3-6 patients receive escalating doses of ganciclovir until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities. Patients are followed at 3 weeks, 4 weeks, 60 days, then every 2 months for 6 months, and then every 3 months for 1.5 years.

PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study.

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma

National Cancer Institute (NCI)

National Human Genome Research Institute (NHGRI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma	NCT00005057	Melanoma (Skin)	adenovirus RSV-... ganciclovir	18 Years -	National Cancer Institute (NCI)
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma	NCT00005057	Melanoma (Skin)	adenovirus RSV-... ganciclovir	18 Years -	National Cancer Institute (NCI)

Spots Global Cancer Trial Database for superficial spreading malignant melanoma